# Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

> **NCT01239069** · PHASE2 · COMPLETED · sponsor: **Santen Inc.** · enrollment: 140 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** DE-110 ophthalmic suspension high dose
- **DRUG:** DE-110 ophthalmic suspension low dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01239069
- **Lead sponsor:** Santen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2014-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01239069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01239069, "Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01239069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*